Biography
Research Topics
Multi-Disciplinary Training Area
Miriam Merad, MD, PhD
CHAIR | Immunology & Immunotherapy
DIRECTOR, PRECISION IMMUNOLOGY INSTITUTE
PROFESSOR | Immunology & Immunotherapy
PROFESSOR | Oncological Sciences
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Dermatology
CHAIR | Immunology & Immunotherapy
DIRECTOR, PRECISION IMMUNOLOGY INSTITUTE
PROFESSOR | Immunology & Immunotherapy
PROFESSOR | Oncological Sciences
PROFESSOR | Medicine, Hematology and Medical Oncology
PROFESSOR | Dermatology
Education
MD, University of Algiers
Residency, University Paris VII (Interne des hopitaux de Paris)
MS (DEA), University Paris VII
PhD, Stanford University and University Paris VII
Postdoctoral Fellow, Stanford University
Honors & Awards
2014
Endowed Professorship
Icahn School of Medicine at Mount Sinai
Video
Office Locations
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Merad during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Morphic Inc.
- Morphic
- Genenta
- Compugen, Inc
- Innate pharma, inc
- Myeloid therapeutic
- nirogy
- oncoresponse
- Dren Bio, Inc
- Myeloid therapeutics
- asher bio, Inc
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Morphic
- Compugen, Inc
- nirogy
- oncoresponse
- Dren Bio, Inc
- Myeloid therapeutics
- asher bio, Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Merad during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Morphic Inc.
- Morphic
- Genenta
- Compugen, Inc
- Innate pharma, inc
- Myeloid therapeutic
- nirogy
- oncoresponse
- Dren Bio, Inc
- Myeloid therapeutics
- asher bio, Inc
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Morphic
- Compugen, Inc
- nirogy
- oncoresponse
- Dren Bio, Inc
- Myeloid therapeutics
- asher bio, Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.